PARP1 and cancer: Our findings warrant potential deleterious effects of current PARP1/2 inhibitor cancer drugs to exacerbate bone metastasis and trigger bone loss; provide key insights for personalized medicine and tailored treatment using PARP1/2 dual inhibitors by revealing distinct effects on bone metastasis, depending on cancer cell BRCA status and PARP inhibitor sensitivity.